Beam Therapeutics Inc.

NasdaqGS:BEAM 株式レポート

時価総額：US$3.0b

Beam Therapeutics マネジメント

マネジメント 基準チェック /44

Beam Therapeuticsの CEO はJohn Evansで、 Jan2017年に任命され、 の在任期間は 9.25年です。 の年間総報酬は$ 5.82Mで、 13%給与と87%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.92%を直接所有しており、その価値は$ 28.08M 。経営陣と取締役会の平均在任期間はそれぞれ5.7年と5.3年です。

主要情報

John Evans

最高経営責任者

US$5.8m

報酬総額

CEO給与比率12.98%
CEO在任期間9.3yrs
CEOの所有権0.9%
経営陣の平均在職期間5.7yrs
取締役会の平均在任期間5.3yrs

経営陣の近況

Recent updates

BEAM: Liver Editing Pipeline And Regulatory Momentum Will Drive Future Repricing

Beam Therapeutics' analyst price target increased by $4, with analysts pointing to Q4 results, progress on Sickle Cell Disease and AATD programs, new liver-directed initiatives such as BEAM-304, and non-dilutive financing as key supports for the revised outlook. Analyst Commentary Recent Street research around Beam Therapeutics has focused on the Q4 print, progress in Sickle Cell Disease and AATD, and the expansion of its liver targeted base editing programs, alongside the use of non dilutive financing to support the pipeline.

BEAM: FDA Alignment And Liver Programs Will Drive Future Upside Repricing

Analysts have nudged the fair value estimate for Beam Therapeutics higher to $51.20 from $50.27, citing a series of recent price target increases related to progress in its liver-targeted programs, Sickle Cell Disease plans, and non-dilutive financing support. Analyst Commentary Recent research coverage on Beam Therapeutics has centered on updated price targets, expanded liver-directed programs, progress in Sickle Cell Disease, and the use of non-dilutive financing to support potential commercialization efforts.

BEAM: FDA Alignment And Liver Programs Will Drive Future Repricing

Analysts have nudged their average price target for Beam Therapeutics slightly higher, supported by recent target increases across several firms that point to growing confidence in the company’s base editing pipeline, new liver programs, regulatory progress, and non dilutive financing, even as expectations for revenue growth are tempered and profit margin assumptions improve alongside a lower implied future P/E multiple. Analyst Commentary Recent research coverage on Beam Therapeutics clusters around higher price targets, new liver focused programs, regulatory updates, and fresh non dilutive financing, with most commentary tilting positive but still flagging execution and program risk.

BEAM: FDA Alignment And New Liver Programs Will Drive Future Repricing

Analyst price targets for Beam Therapeutics have moved higher recently, with several firms lifting their views into a roughly $26 to $75 range. They point to progress in sickle cell BLA plans, new liver-directed programs such as BEAM-304, and non-dilutive financing that supports ongoing pipeline development.

Liver Base Editing Platform Will Transform Rare Disease Treatment Over The Long Term

Catalysts About Beam Therapeutics Beam Therapeutics focuses on base editing therapies aimed at providing onetime genetic treatments for serious diseases. What are the underlying business or industry changes driving this perspective?

Beam Therapeutics: Great Potential, But Patience Is Needed

Feb 27

BEAM: FDA Program Alignment On Sickle Cell Will Drive Future Repricing

Analysts have raised their average price targets for Beam Therapeutics by a few dollars, reflecting progress on sickle cell regulatory plans, new liver-focused programs such as BEAM-304 for phenylketonuria, and recent non-dilutive financing that supports the broader clinical pipeline. Analyst Commentary Recent research updates show a cluster of higher price targets around Beam Therapeutics, with most commentary focusing on execution in sickle cell disease, progress in liver programs, and the new non dilutive financing structure.

Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway

Catalysts About Beam Therapeutics Beam Therapeutics develops base editing genetic medicines that aim to provide onetime treatments for serious diseases such as sickle cell disease, alpha-1 antitrypsin deficiency and phenylketonuria. What are the underlying business or industry changes driving this perspective?

BEAM: FDA Program Alignment And Upcoming Data Readout Will Drive Repricing

Analysts have modestly raised their price targets on Beam Therapeutics, with one firm lifting its view by $4 to $45. The firm cited clearer FDA alignment on key programs and the potential for an accelerated review process as key supports for the updated outlook.

BEAM: FDA Alignment And Upcoming Pulmonary Data Will Drive Bullish Repricing

Analysts have nudged their price targets on Beam Therapeutics higher, with the revised fair value estimate moving from about US$45.92 to roughly US$47.21. They cite improved confidence in the company’s FDA alignment on key programs, upcoming BEAM-302 data, and a lower assumed future P/E multiple alongside updated sector views.

Next Milestones For Beam in 2026.

We now await the JP Morgan health conference. John Evans is set to speak on 13th January.

Beam Therapeutics will revolutionize hospital throughput with breakthrough gene therapy

Beam Therapeutics ($BEAM) has effectively solved the "Gene Therapy Commercialization Problem." While competitors like Vertex ($VRTX) have proven the science works, Beam’s ASH 2025 data confirms it has the superior business model. The new data validates a "Process Efficiency Moat" that structurally lowers Cost of Goods Sold (COGS) and doubles hospital throughput capacity, positioning BEAM-101 as the preferred "Standard of Care" for hospital CFOs. 1.

Beam Rewrites Gene Therapy Playbook with Base Editing Breakthrough

Beam Therapeutics (BEAM) Just Validated the "Best-in-Class" Thesis Headline: Beam Therapeutics: ASH Data Confirms "Best-in-Class" Commercial Profile for Sickle Cell The investment thesis for Beam Therapeutics (NASDAQ: BEAM) has long relied on the promise that Base Editing is not just "another" gene therapy, but a superior industrial platform. The updated N=31 dataset for BEAM-101 (risto-cel) presented at ASH 2025 has now validated this "Best-in-Class" profile with hard data.

Incredible Buying Opportunity

At the Jefferies London Healthcare Conference, Beam President Pino Ciaramella reinforced the "Best-in-Class" thesis for BEAM-101 in Sickle Cell Disease ahead of the upcoming ASH presentation in December. He asserted that the program maintains a "differentiated manufacturing and clinical profile," highlighting a massive commercial advantage: patients require a median of only one mobilization cycle for cell collection versus the industry standard of two to three.

The "Molecular Pencil": Why Beam's Technology is Built to Win

The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.

Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases

Beam Therapeutics’ consensus price target has increased to $45.92, reflecting notable improvements in net profit margin and a lower future P/E, signaling enhanced profitability and a more attractive valuation. What's in the News BEAM-101 for sickle cell disease received FDA RMAT and orphan drug designations; updated Phase 1/2 BEACON data show strong, durable increases in fetal hemoglobin, with sustained safety and efficacy for 17 treated patients.

Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?

Jul 23
Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?

Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now

May 29
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now
User avatar

Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases

Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential.

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 21

Beam Therapeutics: Single-Base Editing Seems To Work

Mar 10

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jan 31
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts

Jan 22

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Dec 20
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

CEO報酬分析

Beam Therapeutics の収益と比較して、John Evans の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2025US$6mUS$755k

-US$80m

Sep 30 2025n/an/a

-US$415m

Jun 30 2025n/an/a

-US$399m

Mar 31 2025n/an/a

-US$387m

Dec 31 2024US$6mUS$716k

-US$377m

Sep 30 2024n/an/a

-US$144m

Jun 30 2024n/an/a

-US$143m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$685k

-US$133m

Sep 30 2023n/an/a

-US$314m

Jun 30 2023n/an/a

-US$327m

Mar 31 2023n/an/a

-US$316m

Dec 31 2022US$9mUS$650k

-US$289m

Sep 30 2022n/an/a

-US$315m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$238m

Dec 31 2021US$14mUS$590k

-US$371m

Sep 30 2021n/an/a

-US$401m

Jun 30 2021n/an/a

-US$408m

Mar 31 2021n/an/a

-US$366m

Dec 31 2020US$907kUS$529k

-US$196m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$106m

Dec 31 2019US$2mUS$473k

-US$91m

報酬と市場: Johnの 総報酬 ($USD 5.82M ) は、 US市場 ($USD 7.12M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Johnの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

John Evans (47 yo)

9.3yrs
在職期間
US$5,818,526
報酬

Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2017. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Evans
CEO & Director9.3yrsUS$5.82m0.92%
$ 28.1m
Giuseppe Ciaramella
President6.3yrsUS$3.16m0.21%
$ 6.5m
Sravan Emany
Chief Financial Officer1.3yrsUS$1.30m0.013%
$ 405.4k
Christine Bellon
Chief Legal Officer & Corporate Secretary7yrsUS$1.97m0.11%
$ 3.2m
Amy Simon
Chief Medical Officer5.1yrsUS$2.80m0.017%
$ 528.2k
Feng Zhang
Co-Founderno dataデータなしデータなし
David Liu
Co-Founderno dataデータなしデータなし
J. Joung
Co-Founderno dataデータなしデータなし
Bethany Cavanagh
Senior VP of Financeno dataデータなし0.013%
$ 396.9k
Manmohan Singh
Chief Technology Officerno dataデータなしデータなし
Gopi Shanker
Chief Scientific Officer3.1yrsデータなしデータなし
Holly Manning
Vice President of Investor Relations & External Communicationsno dataデータなしデータなし
5.7yrs
平均在職期間
56yo
平均年齢

経験豊富な経営陣: BEAMの経営陣は経験豊富で経験豊富です（平均在職期間は5.7年）。

取締役

名称ポジション在職期間報酬所有権
John Evans
CEO & Director9.3yrsUS$5.82m0.92%
$ 28.1m
John M. Maraganore
Independent Director4.4yrsUS$465.65k0%
$ 0
Mark Fishman
Independent Lead Director7.9yrsUS$495.23k0.017%
$ 503.0k
Graham Cooper
Independent Director6.5yrsUS$468.15k0%
$ 0
Kathleen Walsh
Independent Director5.3yrsUS$465.65k0%
$ 0
Chirfi Guindo
Independent Director1.3yrsUS$455.65k0%
$ 0
Christi Shaw
Independent Director2.3yrsUS$463.15k0%
$ 0
5.3yrs
平均在職期間
59yo
平均年齢

経験豊富なボード: BEAMの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/04/30 02:05
終値2026/04/30 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Beam Therapeutics Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22

アナリスト機関
William PickeringBernstein
Alec StranahanBofA Global Research
Whitney IjemCanaccord Genuity